Vote Scores

Home / Companies / Apogee Therapeutics, Inc. / 5 Jun 2024

Meeting · year to 30 June 2024107 filers reporting

Apogee Therapeutics, Inc.: meeting of 5 Jun 2024

Votes reported on Form N-PX, item by item

107 Form N-PX filers reported votes at the Apogee Therapeutics, Inc. meeting of 5 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

3 nominees; 58.8% of reported votes for; 50 filers withheld from or voted against at least one nominee.

594 vote records from 107 filers. 45 of the 105 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

57.0% for0.0% against43.0% other42.9% against management107 filers
2

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

198 vote records from 107 filers. 1 of the 105 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

98.1% for0.0% against1.9% other1.0% against management107 filers100.0% for0.0% against0.0% other0.0% against management12,951,008 reported shares
3

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

198 vote records from 107 filers. 6 of the 105 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

93.5% for5.6% against0.9% other5.7% against management107 filers99.8% for0.2% against0.2% against management12,951,008 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Auditor
VanguardForFor
BlackRock and iSharesForFor
FidelityForFor
State Street and SPDRAbstain or withhold *For
American CenturyAbstain or withhold *For
Franklin TempletonAbstain or withhold *For
InvescoForFor
EquitableForFor
Charles SchwabAbstain or withhold *For
Nuveen and TIAAForFor
ProShares and ProFundsAbstain or withhold *For
John Hancock and ManulifeForFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *For
Goldman SachsAbstain or withhold *For
PGIM and PrudentialAbstain or withhold *For
Jackson National fundsAbstain or withhold *For
Northern Trust and FlexSharesAbstain or withhold *For
SEIAbstain or withhold *For
T. Rowe PriceForFor
Lincoln FinancialAbstain or withhold *For
VoyaForFor
First TrustAbstain or withhold *For
NationwideAbstain or withhold *For
Victory CapitalAbstain or withhold *For
Brighthouse FundsAbstain or withhold *For
Guggenheim and RydexAbstain or withhold *For
BNY MellonForFor
PrincipalForFor
Pacific Life fundsForFor
Global XAbstain or withhold *For
AllianceBernsteinForFor
Hartford FundsForFor
DWSAbstain or withhold *For
MassMutualForFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Apogee Therapeutics, Inc. meeting?

107 Form N-PX filers reported votes at the meeting of 5 Jun 2024. The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Apogee Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Apogee Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Apogee Therapeutics, Inc. with a meeting date within three days of 5 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.